Great Point Partners’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Great Point Partners’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-9,085	Closed	-$132K	–	53
2018 Q4	$132K	Sell	9,085 -19,486	-68%	-$795K	0.02%	39
2018 Q3	$2M	Buy	+28,571	New	+$2.17M	0.31%	26
2017 Q4	–	Sell	-41,649	Closed	-$2.83M	–	47
2017 Q3	$2.83M	Buy	41,649 +759	+2%	+$62K	0.55%	32
2017 Q2	$3.86M	Sell	40,890 -3,049	-7%	-$350K	0.69%	31
2017 Q1	$6.3M	Hold	43,939	–	–	1.25%	24
2016 Q4	$5.57M	Buy	43,939 +13,551	+45%	+$1.89M	1.14%	22
2016 Q3	$4.65M	Sell	30,388 -8,536	-22%	-$1.2M	1.19%	19
2016 Q2	$4.48M	Sell	38,924 -362	-0.9%	-$40.1K	1.28%	20
2016 Q1	$4.46M	Hold	39,286	–	–	1.6%	22
2015 Q4	$7.4M	Buy	39,286 +23,810	+154%	+$4.45M	3.11%	10
2015 Q3	$2.63M	Buy	15,476 +3,374	+28%	+$1.22M	1.04%	26
2015 Q2	$7.65M	Buy	12,102 +7,156	+145%	+$3.8M	2.98%	11
2015 Q1	$2.54M	Buy	+4,946	New	+$2.5M	1.12%	23
2014 Q2	–	Sell	-922	Closed	-$1.28M	–	44
2014 Q1	$1.28M	Buy	+922	New	+$1.07M	0.67%	33

Other funds holding VIRX

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Great Point Partners's VIRX Position: Q1 2019 in Review

Great Point Partners sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2019, closing a stake of 9,085 shares — an estimated $132K sold.

Great Point Partners first reported a position in VIRX in Q1 2014 and held it in 14 quarters. The position peaked at $7.65M in Q2 2015. 44 funds tracked by Wall St. Rank hold VIRX as of Q1 2019.

Great Point Partners reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Great Point Partners sold 9,085 Viracta Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $132K.
Great Point Partners first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 14 quarters.
Great Point Partners's Viracta Therapeutics, Inc. Common Stock position peaked at $7.65M in Q2 2015.
44 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Great Point Partners's 13F filing for Q1 2019, filed 14 May 2019.